These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 15636681)

  • 21. Update in the management of patients with hormone-refractory prostate cancer.
    Moore CN; George DJ
    Curr Opin Urol; 2005 May; 15(3):157-62. PubMed ID: 15815191
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Second-line chemotherapy for advanced hormone-refractory prostate cancer.
    Garmey EG; Sartor O; Halabi S; Vogelzang NJ
    Clin Adv Hematol Oncol; 2008 Feb; 6(2):118-22, 127-32. PubMed ID: 18347563
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapeutic options for hormone-refractory prostate cancer in 2007.
    Hadaschik BA; Gleave ME
    Urol Oncol; 2007; 25(5):413-9. PubMed ID: 17826663
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel chemotherapies in development for management of castration-resistant prostate cancer.
    Tewari AK; George DJ
    Curr Opin Urol; 2013 May; 23(3):220-9. PubMed ID: 23511791
    [TBL] [Abstract][Full Text] [Related]  

  • 25. State-of-the-art treatment of metastatic hormone-refractory prostate cancer.
    Goodin S; Rao KV; DiPaola RS
    Oncologist; 2002; 7(4):360-70. PubMed ID: 12185298
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Therapy of hormone refractory prostate cancer: new standards, new trends].
    Wülfing C; Bierer S; Bögemann M; Piechota H; Hertle L
    Aktuelle Urol; 2005 Aug; 36(4):342-8. PubMed ID: 16110408
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [New drugs in metastatic castration-resistant prostate cancer].
    Albiges L; Loriot Y; Gross-Goupil M; de La Motte Rouge T; Blesius A; Escudier B; Massard C; Fizazi K
    Bull Cancer; 2010 Jan; 97(1):149-59. PubMed ID: 20022854
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Management of patients with hormone refractory prostate cancer.
    Muthuramalingam SR; Patel K; Protheroe A
    Clin Oncol (R Coll Radiol); 2004 Dec; 16(8):505-16. PubMed ID: 15630842
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Systemic therapy after first-line docetaxel in metastatic castration-resistant prostate cancer.
    Beardsley EK; Chi KN
    Curr Opin Support Palliat Care; 2008 Sep; 2(3):161-6. PubMed ID: 18685415
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Taxanes in the chemotherapy of hormone-refractory prostate carcinoma].
    Johannsen M; Wilke K; Schnorr D; Loening SA
    Urologe A; 2004 Feb; 43(2):160-7. PubMed ID: 14991117
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Plasma and tissue insulin-like growth factor-I receptor (IGF-IR) as a prognostic marker for prostate cancer and anti-IGF-IR agents as novel therapeutic strategy for refractory cases: a review.
    Ozkan EE
    Mol Cell Endocrinol; 2011 Sep; 344(1-2):1-24. PubMed ID: 21782884
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epothilones in prostate cancer.
    Kelly WK
    Urol Oncol; 2011; 29(4):358-65. PubMed ID: 19914096
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Endothelin receptor antagonists in the treatment of prostate cancer.
    Lassiter LK; Carducci MA
    Semin Oncol; 2003 Oct; 30(5):678-88. PubMed ID: 14571415
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Chemotherapy of the hormone-refractory prostate cancer].
    Heine K; Wolff JM
    Aktuelle Urol; 2004 Jun; 35(3):209-14. PubMed ID: 15258854
    [TBL] [Abstract][Full Text] [Related]  

  • 35. P450-dependent enzymes as targets for prostate cancer therapy.
    De Coster R; Wouters W; Bruynseels J
    J Steroid Biochem Mol Biol; 1996 Jan; 56(1-6 Spec No):133-43. PubMed ID: 8603034
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hormone refractory prostate cancer (HRPC): present and future approaches of therapy.
    Di Lorenzo G; De Placido S
    Int J Immunopathol Pharmacol; 2006; 19(1):11-34. PubMed ID: 16569343
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Angiogenesis and anti-angiogenic therapy in prostate cancer.
    Mukherji D; Temraz S; Wehbe D; Shamseddine A
    Crit Rev Oncol Hematol; 2013 Aug; 87(2):122-31. PubMed ID: 23375349
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Management of prostate cancer. Part 3: metastatic disease.
    Shah J; Khaksar SJ; Sooriakumaran P
    Expert Rev Anticancer Ther; 2006 May; 6(5):813-21. PubMed ID: 16759171
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New standards in the chemotherapy of metastatic hormone-refractory prostate cancer.
    Sava T; Basso U; Porcaro A; Cetto GL
    Expert Rev Anticancer Ther; 2005 Feb; 5(1):53-62. PubMed ID: 15757438
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Emerging therapies in metastatic castration-sensitive and castration-resistant prostate cancer.
    MacVicar GR; Hussain MH
    Curr Opin Oncol; 2013 May; 25(3):252-60. PubMed ID: 23511665
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.